Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Current Taxes (2017 - 2019)

CytomX Therapeutics (CTMX) has disclosed Current Taxes for 3 consecutive years, with $13.4 million as the latest value for Q1 2019.

  • For the quarter ending Q1 2019, Current Taxes rose 1192.17% year-over-year to $13.4 million, compared with a TTM value of $13.4 million through Mar 2019, up 1192.17%, and an annual FY2018 reading of $13.3 million, up 1333800.0% over the prior year.
  • Current Taxes was $13.4 million for Q1 2019 at CytomX Therapeutics, roughly flat from $13.3 million in the prior quarter.
  • Across five years, Current Taxes topped out at $13.4 million in Q1 2019 and bottomed at $1000.0 in Q4 2017.
  • Average Current Taxes over 3 years is $5.9 million, with a median of $3.8 million recorded in 2018.
  • The sharpest move saw Current Taxes surged 1333800.0% in 2018, then surged 1192.17% in 2019.
  • Year by year, Current Taxes stood at $1000.0 in 2017, then soared by 1333800.0% to $13.3 million in 2018, then rose by 0.26% to $13.4 million in 2019.
  • Business Quant data shows Current Taxes for CTMX at $13.4 million in Q1 2019, $13.3 million in Q4 2018, and $5.0 million in Q3 2018.